2025.May.01
OBI-902 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial
Date of occurrence of the event:2025/05/01 New drug name or code:OBI-902 TROP2 ADC Indication: OBI-902 is the first antibody-drug conjugate (ADC) developed using OBI’s proprietary GlycOBI ADC enabling technologies and targets TROP2. The asset has consistently shown superior antitumor activities across multiple tumor types in various animal models. GlycOBI is a glycan-based site-specific conjugation technology, […]
This article is password protected.
To view the content, please enter your password in the field below